Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In this Phase 3 trial of 934 men with advanced prostate cancer, oral relugolix achieved sustained testosterone suppression in 96.7% of men compared with…
Pfizer is paying Myovant $650 million up front to co-commercialize the oral prostate cancer drug Orgovyx in the U.S. and Canada. The deal builds on Pfizer's…
Sumitovant to acquire all outstanding Myovant shares not already owned for $27.00/share cash ($1.7B; ~$2.9B total company value); Myovant to become a wholly…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Myovant and Pfizer announced a US/Canada collaboration to jointly develop and commercialize Orgovyx (relugolix) in advanced prostate cancer and relugolix combination tablet in women's health. Myovant received $650M upfront plus $200M regulatory milestones for relugolix combo tablet women's health approvals and tiered sales milestones up to $3.5B+, total deal up to $4.2B. Profits and certain expenses split 50/50 with Myovant booking revenue. Post-close development: in October 2022 Sumitovant Biopharma (Sumitomo Pharma group), which already held a majority stake, agreed to acquire the remaining Myovant shares at $27.00/share ($1.7B; ~$2.9B total company value); the deal completed March 10, 2023, making Myovant a wholly owned Sumitovant subsidiary and delisting it from the NYSE. The Pfizer collaboration was not terminated and continues under Myovant as a Sumitomo subsidiary.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Myovant Sciences Ltd. (this deal) | 2020 | $4.2B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2020 deals · Pfizer Inc. deals · Oncology deals